NASDAQ:BLFS

BioLife Solutions (BLFS) Stock Price, News & Analysis

$21.96
-0.01 (-0.05%)
(As of 05/17/2024 ET)
Today's Range
$21.63
$22.11
50-Day Range
$15.14
$22.99
52-Week Range
$8.92
$24.50
Volume
246,695 shs
Average Volume
527,731 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.67

BioLife Solutions MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.8% Upside
$23.67 Price Target
Short Interest
Bearish
7.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of BioLife Solutions in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$562,145 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.50) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.60 out of 5 stars

Medical Sector

863rd out of 920 stocks

Electromedical Equipment Industry

18th out of 19 stocks

BLFS stock logo

About BioLife Solutions Stock (NASDAQ:BLFS)

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

BLFS Stock Price History

BLFS Stock News Headlines

Analysts Set BioLife Solutions, Inc. (NASDAQ:BLFS) PT at $23.67
BioLife Solutions (NASDAQ:BLFS) Raised to Buy at Benchmark
BioLife Solutions Inc (BLFS)
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/18/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:BLFS
Employees
409
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.67
High Stock Price Target
$25.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+7.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-66,430,000.00
Pretax Margin
-45.69%

Debt

Sales & Book Value

Annual Sales
$137.30 million
Book Value
$7.24 per share

Miscellaneous

Free Float
44,788,000
Market Cap
$1.01 billion
Optionable
Optionable
Beta
1.69
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

BLFS Stock Analysis - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price target for 2024?

5 brokerages have issued twelve-month price objectives for BioLife Solutions' stock. Their BLFS share price targets range from $22.00 to $25.00. On average, they anticipate the company's stock price to reach $23.67 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2024?

BioLife Solutions' stock was trading at $16.25 at the beginning of the year. Since then, BLFS shares have increased by 35.1% and is now trading at $21.96.
View the best growth stocks for 2024 here
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) released its earnings results on Thursday, May, 9th. The medical equipment provider reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.06. The medical equipment provider earned $31.73 million during the quarter, compared to the consensus estimate of $29.30 million. BioLife Solutions had a negative trailing twelve-month return on equity of 12.89% and a negative net margin of 45.84%. During the same quarter last year, the business earned ($0.27) earnings per share.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.5 million-$100.0 million, compared to the consensus revenue estimate of $105.7 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.33%), William Blair Investment Management LLC (3.81%), Geneva Capital Management LLC (1.94%), Gagnon Securities LLC (1.31%), Russell Investments Group Ltd. (0.43%) and Principal Financial Group Inc. (0.42%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Geraint Phillips, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Sarah Aebersold, Todd Berard and Troy Wichterman.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLFS) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners